Company:  ALLAKOS INC. (ALLK)
Form Type:  4
Filing Date:  3/3/2021 
CIK:  0001564824 
Address:  975 ISLAND DRIVE
SUITE 201
 
City, State, Zip:  REDWOOD CITY, California 94065 
Telephone:  650-597-5002 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$104.50  
Change: 
-3.64 (-3.37%)  
Trade Time: 
Apr 16  
Market Cap: 
$5.59B
Trade ALLK now with 

© 2021  
Description of Business
We are a clinical stage biotechnology company developing lirentelimab (AK002), our wholly owned monoclonal antibody, for the treatment of various mast cell and eosinophil related diseases. Lirentelimab selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. Inappropriately activated mast cells and eosinophils have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Our initial focus is on eosinophilic gastrointestinal diseases which include eosinophilic gastritis ("EG"), eosinophilic duodenitis ("EoD") which has also been referred to as eosinophilic gastroenteritis, and eosinophilic esophagitis ("EoE"); in addition, lirentelimab has the potential to treat a number of other severe diseases. Lirentelimab has received orphan disease status for EG, EoD, and EoE from the U.S.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES